Trial · NCT00762515
Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes
NCT00762515, Phase 3, Completed, Colgate Palmolive; results first posted 2010-12-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes. Trials, record NCT00762515. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00762515
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes
- NCT number
- NCT00762515
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 44 participants, actual
- Lead sponsor
- Colgate Palmolive
- Conditions
- Dental Plaque
- Interventions
- Fluoride, Triclosan, Fluoride
- First posted
- 2008-09-30
- Last updated
- 2010-12-28
- Results first posted
- 2010-12-14
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Control Established Plaque in Adults | 6 weeks | Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth. Total Plaque score=sum of all scores divided by the number of sites (teeth) scored. |
| Secondary | Control Gingivitis in Adults | 6 weeks | Gingivitis Index (GI) is described as Units on a scale 0 to 3 (0 = no inflammation,1 = Mild inflammation - slight change in color and little change in texture 2 = Moderate inflammation - moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding. GI score = Sum of all scores divided by the number of sites (teeth scored). |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Control Established Plaque in Adults | 6 weeks | Units on a scale | MEAN | |
| SECONDARY | Control Gingivitis in Adults | 6 weeks | Units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Control Established Plaque in Adults | A -Placebo Comparator | 2.42 | Standard Deviation 0.47 | Units on a scale | |
| Control Established Plaque in Adults | B- Active Comparator | 2.45 | Standard Deviation 0.53 | Units on a scale | |
| Control Gingivitis in Adults | A -Placebo Comparator | 0.54 | Standard Deviation 0.16 | Units on a scale | |
| Control Gingivitis in Adults | B- Active Comparator | 0.63 | Standard Deviation 0.19 | Units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | A -Placebo Comparator | 22 | |
| Overall Study | STARTED | B- Active Comparator | 22 | |
| Overall Study | COMPLETED | A -Placebo Comparator | 22 | |
| Overall Study | COMPLETED | B- Active Comparator | 22 | |
| Overall Study | NOT COMPLETED | A -Placebo Comparator | 0 | |
| Overall Study | NOT COMPLETED | B- Active Comparator | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | A -Placebo Comparator | ||
| Total, all-cause mortality | B- Active Comparator | ||
| Total, other adverse events | A -Placebo Comparator | 0 | 22 |
| Total, other adverse events | B- Active Comparator | 0 | 22 |
| Total, serious adverse events | A -Placebo Comparator | 0 | 22 |
| Total, serious adverse events | B- Active Comparator | 0 | 22 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| B- Active Comparator vs A -Placebo Comparator: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00762515
GET https://conductscience.org/api/trials/v1/NCT00762515/registered